within Pharmacolibrary.Drugs.ATC.L;

model L01XX57
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 45.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5.0 / 1000000,
    adminCount     = 1,
    Vd             = 0.5,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Plitidepsin is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. The drug exhibits antitumor and antiviral activities by targeting the eukaryotic elongation factor eEF1A, disrupting protein synthesis. Plitidepsin has been approved for the treatment of multiple myeloma in some countries and has been under investigation for its potential use in COVID-19 and other conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult patients with relapsed/refractory multiple myeloma following intravenous administration in clinical trials.</p><h4>References</h4><ol><li><p>van Andel, L, et al., &amp; Beijnen, JH (2017). Pharmacokinetics and excretion of . <i>Investigational new drugs</i> 35(5) 589–598. DOI:<a href=&quot;https://doi.org/10.1007/s10637-017-0432-5&quot;>10.1007/s10637-017-0432-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28111728/&quot;>https://pubmed.ncbi.nlm.nih.gov/28111728</a></p></li><li><p>Nalda-Molina, R, et al., &amp; Perez-Ruixo, JJ (2009). Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. <i>Cancer chemotherapy and pharmacology</i> 64(1) 97–108. DOI:<a href=&quot;https://doi.org/10.1007/s00280-008-0841-4&quot;>10.1007/s00280-008-0841-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18941750/&quot;>https://pubmed.ncbi.nlm.nih.gov/18941750</a></p></li><li><p>Izquierdo, MA, et al., &amp; Smyth, JF (2008). Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 14(10) 3105–3112. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-07-1652&quot;>10.1158/1078-0432.CCR-07-1652</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18483378/&quot;>https://pubmed.ncbi.nlm.nih.gov/18483378</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX57;
